According to Zacks, “Inventiva S.A. is a clinical-stage biopharmaceutical company. It is focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Inventiva S.A. is based in Daix, France. “
Inventiva stock traded down $0.13 during midday trading on Friday, reaching $9.05. The company’s stock had a trading volume of 5,405 shares, compared to its average volume of 5,677. The stock’s 50-day simple moving average is $10.24 and its 200-day simple moving average is $11.98. Inventiva has a 52-week low of $8.00 and a 52-week high of $16.93.
About Inventiva (Get Rating)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.
- Get a free copy of the StockNews.com research report on Inventiva (IVA)
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.